Wall Street analysts are speculating that the popular diabetes and weight loss medication Ozempic could be subject to federal government price negotiations next year as part of the Department of Health and Human Service‘s new program to lower Medicare prescription prices.

Last week, the Biden administration announced the final negotiated prices for the first 10 drugs selected as the most expensive medications covered by Medicare as part of the negotiation program established by the 2022 Inflation Reduction Act, which was passed by Democrats.